Endocrine complications of hematopoietic stem cell transplantation.
Advances in hematopoietic stem cell transplantation (HSCT) have resulted in broader indications for this therapeutic modality in both malignant diseases and nonmalignant conditions. This article focuses on the late endocrine abnormalities that are most commonly observed following successful HSCT, with a special emphasis on pediatric HSCT recipients, for whom long-term follow-up data are increasingly available.
Chemaitilly
Wassim
W
Department of Pediatrics, Schneider Children's Hospital, 269-01 76th Avenue, New Hyde Park, NY 11040, USA.
Sklar
Charles A
CA
D015519:Bone Density; D004700:Endocrine System Diseases / Q000209:etiology*; D005260:Female; D005947:Glucose / Q000378:metabolism; D006062:Gonadotropins / Q000172:deficiency; D006130:Growth Disorders / Q000209:etiology; D013006:Growth Hormone / Q000172:deficiency; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D012098:Reproduction; D013959:Thyroid Diseases / Q000209:etiology; D013972:Thyrotropin / Q000172:deficiency; D019172:Transplantation Conditioning / Q000009:adverse effects; D014916:Whole-Body Irradiation / Q000009:adverse effects
D006062:Gonadotropins; D013972:Thyrotropin; D013006:Growth Hormone; D005947:Glucose